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Study of Helicobacter pylori in Type 2 diabetes mellitus patients with
dyspepsia
AIM
The aim of the study was to determine the frequency of Helicobacter pylori (H.
pylori) infection in Type 2 diabetic and non-diabetic patients with dyspepsia.
MATERIALS AND METHODS
This was a prospective case control study done in Department of Digestive
Health and Diseases(DDHD),Government peripheral
hospital,Annanagar,Chennai.A total of 100 patients with 50 in each arm were
included in the study protocol.Upper gastrointestinal endoscopy was done  with
biopsies taken from  antrum and body of stomach.The biopsy samples were
subjected to rapid urease test and routine histopathology. For all Type 2 diabetic
patients, HbA1c, Fasting and Post prandial blood sugar were done.
RESULTS
Our study showed 40/48(83.3%) patients were rapid urease test positive for
helicobacter pylori infection as compared to 22/47(46.8%) of rapid urease test
positive for helicobacter pylori infection in non diabetic controls proving that
infection with helicobacter pylori is increased in Type 2 diabetics with
dyspepsia which was statistically highly significant( p value-0.001). Also type 2
diabetic patients’ glycemic status was compared to helicobacter pylori infection
by rapid urease test. According to their HbA1c levels they were divided into 3
groups of less than 7(good control), 7 to 9(poor control) and more than 9(bad
control).using pearson chi square test the association of glycemia in all three
groups was not statistically significant (p-value=0.254).There was a discordance
between helicobacter pylori diagnosed by rapid urease test and by
histopathology examination which was done by routine hematoxylin and eosin
stain.(62/95 rapid urease test positive as  compared to 50/95 by histopathology).
CONCLUSION
This study proves that the prevalence of helicobacter pylori is  high in type 2
diabetic patients than non-diabetic patients with dyspepsia. Glycemic levels in
Type 2 diabetic patients had no statistically significant correlation to
Helicobacter pylori positivity by rapid urease test.
KEY WORDS: Helicibacter pylori, Type 2 Diabetes mellitus, Rapid urease test,
Dyspepsia, HbA1c
1INTRODUCTION
Helicobacter pylori infection remains one of the most common
chronic bacterial infections in humans. Estimates suggest that more than
half the world's population is infected with the bacterium and genetic
sequence analysis proposes that humans have been infected for more than
58,000 years at a time when they first migrated from Africa.[1]
Helicobacter pylori are unique bacteria ideally suited to live in the acidic
environment of the human stomach. Their spiral shape and multiple
unipolar flagella allow them to move freely through the gastric mucous
layer, where they remain protected from low gastric pH.[2] Organisms
produce large amounts of urease, an enzyme that hydrolyzes urea to
alkaline ammonia and CO2. This permits the bacteria to further control
the  pH  of  their  microenvironment.  Urease  is  also  the  basis  of  clinical
diagnostic tests (urea breath test and rapid urea biopsy tests) for infection.
H. pylori remain difficult and tedious to culture because they grow slowly
and require specialized culture media and a controlled microaerophilic
environment.
Diabetes mellitus (DM) refers to a group of common metabolic
disorders that share the phenotype of hyperglycemia. Depending on the
etiology of the DM, factors contributing to hyperglycemia include
2reduced insulin secretion, decreased glucose utilization, and increased
glucose  production.   In  Type  2  diabetes  mellitus  which  has  a  genetic
basis, there is insulin resistance as well as decreased production of
insulin. The metabolic dysregulation associated with DM causes
secondary pathophysiologic changes in multiple organ systems that
impose a tremendous burden on the individual with diabetes and on the
health care system.
The National Urban Diabetes Survey (NUDS), a population based
study was conducted in six metropolitan cities across India and recruited
11,216 subjects aged 20 yr and above representative of all socio-
economic strata. The study reported that the age standardized prevalence
of  type  2diabetes  was  12.1  per  cent.  This  study  also  revealed  that  the
prevalence in the southern part of India to be higher-13.5 per cent in
Chennai.[3]Various studies conducted in different parts of the world have
given conflicting results regarding the association between Type 2
Diabetes mellitus and H.pylori.
Since there are only a few studies in our country on the association
of Helicobacter pylori and Type 2 diabetes mellitus, we conducted this
study in our institute.
3REVIEW OF LITERATURE
Helicobacter pylori, which persistently colonizes the stomachs of
~50% of the world’s human population, is the main risk factor for peptic
ulceration  as well as for gastric adenocarcinoma and gastric MALT
(mucosa associated lymphoid tissue) lymphoma .Treatment for H. pylori
has revolutionized the management of peptic ulcer disease, providing a
permanent cure in many cases. The prevention of H. pylori colonization
could potentially represent primary prevention of gastric malignancy and
peptic ulceration.
EPIDEMIOLOGY
H. pylori have been demonstrated worldwide in individuals of all
ages, infection is more common and acquired at an earlier age in
developing countries compared with industrialized nations.[4,5] In
developing nations, the majority of children become infected before the
age of 10, and during early childhood spontaneous elimination of bacteria
and subsequent reinfection is quite common. Infection persists in older
children and adults so that in the developing areas of the world H. pylori
prevalence can reach more than 80% by age 50. Spontaneous clearance
often occurs and there is less chance of reinfection; thus, persistent
childhood infection is much less frequently seen than in less-developed
4countries.[4] In fact, serologic evidence of H. pylori is uncommon in
children before age 10, but rises to 10% in adults between 18 and 30
years of age and further increases to 50% in those 60 or older.[4]
Especially in developing countries, contaminated water might
serve as an environmental source of bacteria because the organism can
remain viable for several days in water.[6] Bacterial deoxyribonucleic acid
(DNA) can be found in samples of municipal water from endemic areas
of  infection  but  whether  viable  H.  pylori  are  present  remains  to  be
proven.[7] In countries where infection is common, children who drink
untreated stream water, eat uncooked vegetables, or swim in rivers and
streams are more likely to harbour the bacteria, providing further indirect
evidence of an environmental source of organisms.
Infected gastric secretions can serve as a source of bacterial
transmission. Iatrogenic infection has occurred during the use of a variety
of inadequately disinfected gastric devices, endoscopes, and endoscopic
accessories.[8]  Gastroenterologists and nurses appear to be at greater risk
for acquiring H. pylori, presumably due to occupational contact with
infected gastric secretions.[9] Mandated universal precautions,
standardized equipment disinfection, and use of video-endoscopes that
5reposition the instrument channel away from the mouth should reduce
such iatrogenic and occupational transmission.
Natural transmission could occur through contact with infected
vomitus during an acute illness[10] or with regurgitated material from an
infected child
PATHOGENESIS
Specific genetic or phenotypic factors in infectious agents have
been implicated as single causal factors in a variety of infectious diseases
and associated outbreaks. However, H. pylori infection alone appears
insufficient to fully explain the spectrum of diseases that is associated
with chronic infection. Research over the past quarter century suggests
that the pathogenicity of  depends on bacterial and host factors in addition
to less well-defined environmental conditions. Virulence of this
infectious pathogen is based on bacterial properties that allow
colonization and adaptation to the gastric environment and a host
response that contributes to the host physiologic and histologic changes.
COLONIZATION AND VIRULENCE FACTORS
H. pylori show a strict tropism for the gastric mucosa or intestinal
sites in which there is gastric metaplasia. H. pylori do not colonize
6epithelium in the stomach that has undergone intestinal metaplastic
change, possibly due to the production of antimicrobial factors that select
against colonization.  H. pylori rarely colonize the deeper portions of the
gastric glandular mucosa, where O-glycans that impair H. pylori growth
are found.[11] H. pylori decreases the expression of the antibacterial
molecule, secretory leukocyte protease inhibitor,[12] thereby removing an
element of the host response that would be detrimental to the persistent
infection.
After H. pylori migrate to the gastric epithelium, the organism
attaches to host cells and may damage them in order to obtain nutrients
from the subsequent inflammatory exudate or transudate. A key
interaction between the bacteria and gastric epithelium involves a
segment of bacterial DNA referred to as the cag pathogenicity island (cag
PAI).
Genes  within  the  cag  PAI  encode  proteins  that  provide  a  type  IV
secretion apparatus (i.e., cagE) that allows bacterial macromolecules to
translocate into the host cell (i.e., cagA).[13] cag PAI plays an important
role in the pathogenesis of gastritis in humans[13] because  H.  pylori
bearing the cag PAI are associated with increased interleukin-8 (IL-8)
expression and inflammation in gastric mucosal biopsy specimens and
7increased IL-8 expression and apoptosis in vitro.[14] Human  studies  in
which duodenal ulceration occurred more frequently in children carrying
strains expressing cagE associated with higher levels of gastric IL-8[15]
corroborate animal and in vitro studies.
Gastric acid secretion is a major function of the gastric mucosa that
is regulated by a variety of neural, endocrine, and immune factors.[16]
Elevated fasting and meal- or hormone-stimulated levels of gastrin are
well documented in H.pylori infection, and there is evidence that gastrin
expression is regulated by bacterial factors and cytokines. Expression of
somatostatin, an acid-inhibitory peptide, is diminished in infected
individuals as is duodenal bicarbonate secretion. The net effect of
H.pylori infection on acid secretion is complex and varies depending on
the duration and distribution of infection and presence of mucosal
atrophy.
Secretion of mucus is also affected by H.pylori infection with
decreased amounts of mucus and gastric mucosal hydrophobicity; these
abnormalities reverse after eradication of infection. Epithelial barrier
function is altered during H.pylori infection as a consequence of both
direct effects of H.pylori and the accompanying inflammatory response
8that collectively increase epithelial cell proliferation and programmed cell
death.[17]
Viral antigens are presented to T cells when infected apoptotic
epithelial cells overlie the Peyer's patch. Engulfment of H.pylori infected
epithelial cells by phagocytes may also be an important mechanism by
which H.pylori  can activate the host response, and it has been shown that
macrophages bind and then engulf gastric epithelial cells that undergo
apoptosis due to infection.[17]
The catabolism of urea by urease provides CO2, which rapidly
neutralizes the bactericidal activity of the peroxynitrate by reacting with it
to form ONO-OCO2. Urease may favour bacterial colonization by
neutralizing some host responses but this also enhances the nitration
potential of ONOO? and may favour mutagenesis of host cell DNA.
Because Th1 cells cannot clear H.pylori, some other T cell subset
may have to be stimulated in order to confer immunity. Studies in animal
models indicate that protective immunity was induced by vaccines for
Helicobacter spp. via Th cells other than Th1 cells, possibly including
Th2 cells. The anti-inflammatory cytokines associated with Th2 cells or
other regulatory subsets of Th cells can attenuate the pathogenic effects
9of  Th1  cells.[18] More direct evidence suggests that IL-4 can decrease
gastritis, an effect that may be mediated by the release of somatostatin.[19]
As gastric responses can be modified by Th2 cells, the role of other
T  cell  subsets,  such  as  regulatory  T  cells  (Treg),  in  the  pathogenesis  of
disease associated with H.pylori infection is being addressed. Depletion
of Treg in neonatal mice leads to autoimmune gastritis,[20] and infection
with H.pylori alleviates autoimmune gastritis induced in neonatal
mice.[21] This suggests that infection may stimulate a subset of anti-
inflammatory T cells that impair excessive inflammation, which could
otherwise lead to the spontaneous clearance of the organism, an effect
that appears to occur in the human mucosa in response to H.pylori
infection.[22]
Antibodies in the gastrointestinal tract are normally of the
immunoglobulin A (IgA) isotype, which are highly adapted for mucosal
protection, conferring protective immunity without activating
complement and stimulating deleterious amounts of inflammation.
During infection with H.pylori the number of IgA producing cells
increases. IgG and IgM are also detected, along with activated
complement.  It  has  been  suggested  that  the  level  of  autoantibodies  in
humans correlates with the severity of gastritis.[17] Local immune
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complexes contribute to gastroduodenal inflammation and tissue damage
during infection and may contribute to autoimmune gastritis.
Monoclonal antibodies that recognize H.pylori cross-react with
human and murine gastric epithelial cells.[23] Adoptive transfer of these
antibodies to recipient mice induces gastritis,[23] as does the transfer of B
cells that recognize heat shock proteins from individuals with
maltoma.[24] Anti-Le antibodies have been described in humans and occur
independently of the Le phenotype of the host but they do not appear to
be autoreactive. Autoantibodies induced in mice may recognize different
targets within the gastric mucosa and even though they may cross-react
with human gastric tissue, autoantibodies induced in humans may have a
completely different specificity.
Infection with H.pylori persists for the life of the host unless there
is some intervention with antibiotics. This observation has led to
investigations as to whether immunity is impaired by immunologic
avoidance or tolerance. Several bacterial factors, including catalase and
urease, antagonize innate host responses. Production of the enzyme
arginase by H.pylori inhibits NO production and may favour bacterial
survival,[25] whereas virulent strains of H.pylori have also been shown to
alter mucus production and phagocytosis.[26]
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CONDITIONS ARISING FROM INFECTION
Infection of the human stomach by H.pylori leads to gastritis,
which initially affects the superficial layers of the mucosa. In some
instances the infection is short lived, but typically the infection results in
a unique pattern of gastritis, so-called chronic active gastritis, which is
essentially a lifelong condition. Chemokines induced by infection lead to
a persistent acute inflammatory infiltrate with neutrophils and other cells
(active inflammation) coexisting with cells characteristic of chronic
inflammation (lymphocytes, macrophages). Most chronically infected
individuals are asymptomatic with somewhere between 10% and 15%
going on to develop peptic ulcer disease, gastric adenocarcinoma, and
lymphoma of the gastric mucosa–associated lymphoid tissue
H.pylori organisms colonize only gastric-type epithelium within
the human host and may colonize tissues outside the stomach when there
is gastric metaplasia of the esophagus or duodenum, or in a Meckel's
diverticulum. The pattern of colonization within the stomach appears to
be an important determinant of H.pylori disease manifestations. It is
unclear exactly what leads to duodenal ulcers associated with H.pylori
infection, but it is thought that hyperacidity associated with antral
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colonization leads to gastric metaplasia of the duodenum, which can then
become colonized, leading to duodenal ulcer in some instances.
Distal gastric infection may also present with erosions and small
ulcers in the gastric antrum, similar in appearance to lesions associated
with anti-inflammatory drug use. Gastric ulcers and gastric
adenocarcinoma occur more often when there is proximal colonization of
the stomach (pan-gastritis), which results in injury to the gastric glands,
leading to atrophic gastritis and associated hypo- or achlorhydria .
The burden of risk of gastric cancer is considered largely
attributable to H.pylori infection, with cag PAI–bearing strains having a
higher association with gastric cancer than cag PAI–negative strains.
Given the burden of gastric cancer worldwide, the risk of infection
seemingly outweighs the benefits in terms of the development of
proximal gastrointestinal tract cancer.
NONGASTRIC DISEASES AND H.PYLORI INFECTION
Over the past two decades a large number of associations with
nongastric diseases and H.pylori infection have been reported including
Raynaud's, scleroderma, idiopathic urticaria, acne rosacea, migraines,
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thyroiditis, and Guillain-Barre syndrome, but the data supporting an
association for this group of conditions are weak or nonexistent.[28]
Associations that have somewhat better levels of evidence for an
association include coronary artery disease, immune thrombocytopenic
purpura,[29,30] and iron deficiency anemia[31] and for the latter two
conditions, eradication of infection may be considered when other
treatments have failed. The proposed mechanisms leading to these
various conditions range from systemic immune reactions, cross-
reactivity of bacterial and host proteins, and events secondary to gastric
mucosal injury.
DIAGNOSIS
The American College of Gastroenterology published updated U.S.
guidelines in 2007 that recommend testing for H.pylori only if a clinician
is prepared to treat a patient with a positive test result.[32] Specific
indications for testing include patients with active or documented history
of uncomplicated or complicated peptic ulcer, early gastric cancer, or
gastric MALT lymphoma. Testing for H.pylori is often recommended in
younger patients with uninvestigated dyspepsia and no “alarm features”
(i.e., early satiety, unexplained weight loss, dysphagia, recurrent
14
vomiting, family history of gastric cancer)[33] and  in  patients  with
functional dyspepsia (symptoms and negative endoscopy).[34]
However, the clinical and cost benefits of H.pylori in the setting of
dyspepsia remain controversial, especially in regions where prevalence of
infection is relatively low and gastroesophageal reflux disease (GERD) as
a cause of symptoms is high.[35] Testing for infection prior to starting
nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce subsequent
ulcers, but this not generally recommended or often done in the United
States, where prevalence of H. pylori is low.[32]
Also there is no general recommendation to test asymptomatic
persons, with the possible exception of those with a family history of
gastric cancer,[36] particularly individuals of Asian, Eastern European, or
Mesoamerican descent, for whom the risk of gastric malignancy is
highest. Occasionally immune thrombocytopenic purpura[30,37] and
refractory iron deficiency anemia[31] respond to eradication of infection,
so decisions to test for H.pylori in these conditions are made on a case-
by-case and regional basis.
Indications for Testing and Treatment of Helicobacter pylori
Infection:
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Supported by evidence
Active peptic ulcer disease (gastric or duodenal ulcer)
Confirmed history of peptic ulcer (not previously treated for H.pylori
infection)
Gastric MALT-lymphoma (low grade)
Following endoscopic resection of early gastric cancer
Uninvestigated dyspepsia (if H.pylori population prevalence high)
Controversial
Functional dyspepsia
GERD
Persons using NSAIDs, especially when first initiating NSAID treatment
Unexplained iron deficiency anemia or immune thrombocytopenic
purpura
Populations at higher risk of gastric cancer (e.g. Asians, Eastern
Europeans, Mesoamericans)
There are endoscopic and non endoscopic means to diagnose
infection, and techniques can directly (histologic demonstration of
organisms, presence of bacterial antigen in the stool, culture) or indirectly
(using urease or an antibody response as a marker of bacteria) detect
H.pylori.[38,39] The appropriate method to choose depends on the clinical
16
situation, population prevalence, and pre-test probability of infection as
well as test availability and cost. In addition, recent use of antibiotics or
proton pump inhibitors can influence results of certain tests.[32]
 DIAGNOSTIC TESTS FOR HELICOBACTER PYLORI
NONENDOSCOPIC
TESTS ADVANTAGES DISADVANTAGES
Serology (qualitative or
quantitative
immunoglobulin G [IgG])
Widely available,
inexpensive, good
NPV
Poor PPV if HP
prevalence is low,
not useful after
treatment
Urea breath test (13C or
14C)
Identifies active
infection, accuracy
(PPV, NPV) not
affected by H. pylori
prevalence, useful
both before and after
treatment
Availability and
reimbursement
inconsistent,
accuracy affected by
PPI and antibiotic
use, small radiation
dose with 14C test
Stool antigen test
Identifies active
infection; accuracy
(PPV, NPV) not
affected by H. pylori
prevalence; useful
both before and after
treatment
(monoclonal test)
Fewer data available
for polyclonal test,
accuracy affected by
PPI and antibiotic
use
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ENDOSCOPIC
TESTS ADVANTAGES DISADVANTAGES
Histology
Excellent sensitivity and
specificity, especially
with special and immune
stains; provides
additional information
about gastric mucosa
Expensive (endoscopy and
histopathology costs),
interobserver variability,
accuracy affected by PPI
and antibiotic use
Rapid urease test
Rapid results, accurate in
patients not using PPIs or
antibiotics, no added
histopathology cost
Requires endoscopy, less
accurate after treatment or
in patients using PPIs
Culture
Specificity 100%, allows
antibiotic sensitivity
testing
Difficult and tedious to
perform; not widely
available; expensive
Polymerase chain
reaction (PCR)
assay
Excellent sensitivity and
specificity, permits
detection of antibiotic
resistance
Not widely available;
technique not standardized;
expensive
Performing endoscopy solely to diagnosis H.pylori infection is not
appropriate; there are three methods—biopsy urease test, histology, and
(less often) culture—to identify the organism during an otherwise
indicated endoscopic procedure. The choice of method depends on the
clinical situation, cost, and test accuracy.[32]
Guidelines propose initially using a biopsy urease test because the
method is quick, easy to perform, relatively inexpensive, and generally
18
accurate. Gastric biopsy material is tested for urease activity by placing
several pieces of tissue in a medium containing urea and a pH reagent.
Bacterial urease hydrolyzes urea-liberating ammonia, producing an
alkaline pH and a resultant colour change of the test medium.[38] Test
results are often positive within minutes to hours.
Several urease test kits are commercially available based on the
methodology described here, differing only with regard to medium (agar
gel or membrane pad) and testing reagents.[38] These test kits are
generally inexpensive but there are added costs associated with obtaining
gastric tissue samples, for example, up-coding diagnostic
esophagogastroduodenoscopy (EGD), to EGD with biopsy. Nevertheless,
biopsy urease testing is less expensive than histology so one proposed
cost-saving measure is to obtain specimens for histology but delay
sending them to the laboratory pending urease test results. Specificity of
the urease tests is 95% to 100% with false-positive tests uncommon.[38,40]
Although reported sensitivity of urease tests is 90% to 95%,
accuracy can be negatively affected by blood in the stomach,[41] and
current or recent use of medications such as antibiotics, bismuth-
containing compounds, or acid inhibitors, especially PPIs.[42] Therefore, a
negative urease test does not necessarily exclude H.pylori infection in an
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individual taking antisecretory medication, a common scenario in patients
referred for endoscopy. Testing samples from multiple regions of the
stomach or stopping offending medication and delaying endoscopy for
several weeks may improve test sensitivity in such patients.
Evaluation of gastric mucosal histology is generally not necessary
to diagnose H.pylori, but it can provide information regarding the activity
and severity of mucosal inflammation. Histology can also detect
metaplasia, dysplasia, and neoplasia.[38] In addition to biopsying
“clinically suspicious” areas, taking multiple biopsies and sampling lesser
and greater curvatures of gastric antrum and body are important,
especially when looking for evidence of multifocal atrophic gastritis
and/or intestinal metaplasia . Histologic examination had been considered
the gold standard for identifying infection, with reported sensitivity and
specificity as high as 95% and 98%, respectively.[43]
However, the distribution and density of organisms can vary within
the stomach resulting in sampling error, particularly in patients taking
antisecretory medications.[32,38] Detecting organisms can be difficult when
standard hematoxylin and eosin staining is used alone, but is less of an
issue when processing tissue with special stains such as Giemsa, silver, or
Genta  or specific immune stains.[39,44]
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H.pylori  are difficult to culture because the organism is fastidious,
slow growing, and requires specialized media and growth
environment.[38,39] In fact the initial isolation of H.pylori occurred by
happenstance when plated cultures incubated over a long holiday
weekend. When culturing for H.pylori, tissue should be obtained before
biopsy forceps become contaminated with formalin and placed in a
container with only a few drops of saline to preserve the specimen during
transport to a local or offsite microbiology facility.[39]
Although culture is not generally recommended, in those with
refractory disease culture with antibiotic sensitivity testing can guide
subsequent treatment, although in vitro sensitivity testing does not always
predict clinical treatment outcome.[39,45]
Most often nonendoscopic tests are used to diagnose H.pylori
infection, and serology remains the most popular method used, although
use of other non-invasive methods that can detect active infection has
increased. Infection incites a systemic immune response, and enzyme-
linked immunosorbent assay (ELISA) technology can detect IgG
antibodies to a variety of bacterial antigens in serum samples.[38,39]
Tests  for  IgA  and  IgM  class  antibodies  are  less  reliable  and  not
recommended.[38] Office-based kits that test whole blood can provide
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results within 30 minutes and permit “point of service” testing. Although
serology is inexpensive, non-invasive and ideally suited to a primary care
setting, the prevalence of H.pylori  in the population being tested
influences its accuracy.[32] The sensitivity of serology is generally quite
high (90% to 100%) but specificity is variable (76% to 96%), especially
if prevalence of H.pylori is low. Therefore, in places where infection is
less common (most areas of the United States), the negative predictive
value of serology is high. On the other hand, the corresponding positive
predictive value is poor, suggesting most often positive results are
actually falsely positive.[32]
So it is best to confirm positive serology results with another
method such as a stool antigen or urea breath test before starting
treatment or to use a test that detects active infection in the first place.
Conversion of a positive serology to negative after treatment suggests
bacterial cure, but in most instances serology remains positive for months
to years even after successful treatment of infection.[46] This “serologic
scar” effectively precludes use of serology to confirm bacterial
eradication after treatment, a practice that is unfortunately still quite
common in the primary care setting even though better tests to confirm
eradication are more widely available.
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The urea breath test (UBT) detects active H.pylori  infection and so
it is useful for making the primary diagnosis, confirming the accuracy of
serology, and documenting successful treatment.[32] UBT  relies  on
bacterial hydrolysis of orally administered urea tagged with a carbon
isotope, either 13C or 14C . Hydrolysis generates ammonia and tagged
CO2, which can be detected in breath samples.[38,39] The 13C test  is  best
for children and pregnant women because it uses a nonradioactive
isotope,  whereas  the  radiation  dose  with  the  14C  test  is  1  microCi[39]
equivalent to one day of background radiation exposure.
The specificity of UBT is more than 95%[32]; therefore, false-
positive results are uncommon. The sensitivity of the test is 88% to 95%
with false-negative results reported in patients taking antisecretory
therapy such as PPIs,[32,42] bismuth, or antibiotics. To improve accuracy,
antibiotics should be stopped at least four weeks and PPIs at least one
week before breath testing.[32] UBT is not accurate in patients who have
had gastric resective surgery.
An immunoassay that detects the presence of bacterial antigens in
stool of infected patients is an alternative nonendoscopic method to
diagnose active H.pylori infection as well as confirm eradication
following treatment. Overall sensitivity and specificity of the stool test
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are comparable to the UBT (94% and 97%, respectively).39,41] A  rapid
H.pylori stool antigen test is available that permits testing during a clinic
visit but it is slightly less accurate than a traditional laboratory based stool
test.[47]
The sensitivity of stool testing is negatively affected by PPIs,
bismuth, and antibiotics, which can decrease bacterial load, so similar
precautions as described earlier for UBT are appropriate when using stool
tests.[39,42]
Polymerase chain reaction is a sensitive method to detect H.pylori
in gastric mucosal biopsies, but it is not practical for routine clinical
diagnosis. It is, however, used for research purposes to identify bacteria
when ordinary culture is difficult, as when testing stool or drinking water
in a community setting, to type organisms during epidemiologic or
transmission studies or for “real time” antibiotic resistance testing of
tissue.[48]
Current recommendations for testing are as follows. A stool
antigen assay or UBT is the preferred non-invasive method for initial
diagnosis of H.pylori because it can detect active infection. Serology is
only useful to exclude H.pylori infection, and positive serology results
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should be confirmed by a test for active infection before starting
treatment.
Endoscopic biopsy is suitable for patients undergoing a diagnostic
endoscopy who are found to have an abnormality such as an ulcer or for
those requiring endoscopy to follow-up a gastric ulcer or suspected
MALT lymphoma. Biopsy urease testing can be used in patients not
taking a PPI or antibiotics when histopathology is not clinically
necessary.
When clinically indicated it is appropriate to confirm successful
eradication of infection with either a UBT or stool antigen test. These
tests should not be performed sooner than four to six weeks after
completion of treatment because earlier testing might yield false-negative
results.
PPIs should be discontinued at least one week prior to testing to
improve accuracy. Post-treatment endoscopy with biopsy is only
necessary if a repeat procedure is clinically indicated to follow up
complicated ulcer disease or other mucosal abnormality, but this should
be delayed for at least four to six weeks after therapy. Sampling multiple
areas of the stomach is important to avoid missing persistent infection
because of density and distribution of bacteria by prior antibiotics and
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concomitant antisecretory medications. Serology is not useful for follow-
up because the test remains positive in most patients for months or even
years after infection is gone.
TREATMENT
Because there is currently no “H.pylori specific” or single
antibiotic available to cure infection, treatment requires combining
several medications. Recommended regimens usually include two
antibiotics dosed several times daily for 7 to 14 days along with acid-
suppressive medication.[49] Attempts to simplify regimens or shorten
treatment duration generally reduce effectiveness. Compliance can be a
problem because taking multiple medications is difficult, and minor
medication-related side effects are frequent. Treatment success can vary
among countries and even within regions of countries, possibly related to
antibiotic-resistant organisms that are more common than previously
appreciated.[49,50] Despite these concerns, treatment regimens are
available that cure H.pylori infection in more 75% of individuals.[51,52]
After cure, annual adult reinfection especially in developed
countries is uncommon, probably less than 1%. Higher rates of
reinfection are reported, but these often include cases that actually
represent recrudescence of the original infection that failed to clear during
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antibiotic treatment.[53] Reinfection tends to be higher in children
especially after spontaneous clearance of a primary infection, and it is
reported to be higher in adults living in areas of the world with high
H.pylori prevalence.[54]
Triple therapy, composed of two antibiotics, Clarithromycin 500
mgs b.d. and Amoxicillin 1 gm b.d. along with a PPI for 7 to 14 days, is
currently the most popular initial treatment for H.pylori. PPI triple
therapy consistently cures more than 80% of infections, especially if
organisms are sensitive to clarithromycin and longer treatment duration
(14 or 10 days vs 7 days) is used. Metronidazole 500 mg b.d can be
substituted for either amoxicillin or clarithromycin, but this is appropriate
only for penicillin-allergic or macrolide-intolerant individuals because
metronidazole resistance is common and can reduce treatment
success.[32,49,51]
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First-Line Treatment of Helicobacter pylori Infection
TREATMENT REGIMEN DUR-ATION
ERADIC-
ATION
RATE
COMMENTS
PPI, clarithromycin 500 mg,
amoxicillin 1000 mg (each
twice daily)
10-14
days 70%-85%
Macrolide resistance
affects eradication
success; not appropriate
for penicillin allergic
individuals or those who
have received a
clarithromycin regimen
in the past
PPI, clarithromycin 500 mg,
metronidazole 500 mg (each
twice daily)
10-14
days 70%-85%
Appropriate for
penicillin-allergic
individuals who have
not received a
clarithromycin-
containing regimen in
the past
PPI, amoxicillin
1000 mg (each
twice daily)
followed by
PPI,
clarithromycin
500 mg,
tinidazole 500
mg (each twice
daily)
5 days
5 days 90%
Appears highly effective
despite clarithromycin
resistance
Bismuth subsalicylate
525 mg, metronidazole
500 mg, tetracycline
500 mg (each four times
daily)
plus
PPI or H2RA (twice
daily)
10-14
days 75%-90%
Inexpensive but
complicated regimen;
consider in penicillin
allergic individual or if
clarithromycin
resistance is suspected;
can be used for
retreatment
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A 10-day sequential regimen (a PPI and amoxicillin 1 g, each
given twice daily for the first 5 days, followed by the PPI, clarithromycin
500 mg, and tinidazole 500 mg, each given twice daily for the remaining
5 days) improved overall eradication rates compared with standard PPI
triple therapy (89% vs. 77 %), but was particularly better for
clarithromycin-resistant bacteria (89% vs. 29%).[55] A pooled analysis of
studies evaluating sequential therapy confirmed its superior efficacy
especially with macrolide-resistant bacterial strains.[56] Such  results  are
encouraging, although most experience with this treatment is
geographically limited to Mediterranean countries. However, there is no
reason to expect different efficacy in other regions.[55] Although used
more  than  a  decade  ago,  dual  regimens  consisting  of  a  single  antibiotic
(amoxicillin or clarithromycin) and a PPI are no longer recommended
because eradication is significantly less than with three drug regimens.[51]
Bismuth-based therapy, which combines a bismuth salt,
metronidazole 500 mg and tetracycline 500 mg each given four times a
day, and daily acid suppression (usually a PPI every day) for two weeks
was actually one of the first therapies used to treat H.pylori. Although it
remains effective (more than 80% eradication), the number of daily pills
and associated frequent minor side effects negatively affect tolerability
and compliance.
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A combination capsule that contains bismuth subcitrate 140 mg,
metronidazole 125 mg, and tetracycline 125 mg is available in the United
States and Canada, simplifying bismuth-based treatment. In a
comparative study, patients treated with three combination capsules four
times daily and PPI twice daily for 10 days had comparable H.pylori
eradication with those treated with traditional PPI triple therapy (88% vs.
83%).[57] Short course (1 to 7 days) bismuth-based treatment[58] has been
evaluated, but consistent long-term cure of infection has not been
confirmed, so abbreviated treatment cannot be recommended.[51]
Initial treatment of H.pylori infection fails in up to 25% of patients
as a result of an infection with antibiotic-resistant organisms, poor
compliance with medication, and patient demographics such as younger
age, smoking, prior antibiotic use, and underlying condition (functional
dyspepsia vs. peptic ulcer).[59,60]
A review of various retreatment regimens reported eradication
rates  of  46%,  70%,  80%,  and  76  %  percent  for  PPI  dual  therapies,  PPI
triple therapies, ranitidine bismuth citrate–based triple therapy and
bismuth-based therapy, respectively.[61] Ranitidine bismuth citrate is no
longer available in the United States. When two new antibiotics are used
during retreatment, cure of infection appears to be superior compared
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with when only one new antimicrobial is used. One more recently
recommended “rescue therapy” includes a PPI, levofloxacin 250 mg, and
amoxicillin 1 g, all given twice daily for 10 days. This combination cures
infection in up to 80% of patients who have failed one or more prior
treatment attempts.
Less well studied, but reported to be 85% effective when used as
retreatment, is a combination of PPI and amoxicillin 1 g, each twice
daily, along with rifabutin 300 mg every day for 10 days. A lower dose of
rifabutin (150 mg) appears to be less effective. Successful retreatment
with regimens substituting furazolidone for metronidazole has also been
reported.
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 Rescue Treatment for Persistent Helicobacter pylori Infection
REGIMEN DURATION ERADICATIONRATE COMMENTS
Bismuth
subsalicylate
525 mg,
metronidazole
500mg,
tetracycline
500 mg (each
four times
daily)
plus
PPI or H2RA
(twice daily)
14 days 70%
Inexpensive but
complicated
regimen, so
compliance should
be emphasized; less
effective as
retreatment than as
initial therapy; full
dose of
metronidazole and
two weeks of
treatment appear
necessary
PPI,amoxicillin
1000mg,
levofloxacin 250
mg (each twice
daily)
10-14 days 57%-91% Limited data fromthe United States
PPI amoxicillin
1000 mg,
rifabutin 150 mg
(each twice daily)
14 days 60%-80%
Expensive; adverse
hematologic events
and drug interactions
possible.
Limited data from
the United States
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As initial treatment for H.pylori, a 10- to 14-day course of standard
PPI  triple  therapy  described  previously  (PPI,  amoxicillin  and
clarithromycin) is recommended but a 10-day sequential regimen would
be an appropriate alternative, especially if clarithromycin-resistant
infection is suspected (see following). If infection persists after this
treatment, bacteria are likely resistant to clarithromycin. Therefore,
retreatment should be with one of the PPI triple regimens noted earlier
that incorporates a different combination of medications or a bismuth-
basedtherapy for 14 days.
Subsequent courses of treatment if necessary should also
incorporate different antibiotic combinations when possible to lessen the
effect of acquired antimicrobial resistance. Although selection of a
treatment regimen based on antibiotic sensitivity testing might improve
subsequent treatment results, this is not routinely recommended.
Primary resistance to antibiotics commonly used to treat H.pylori
varies widely throughout the world.[49] In the United States resistance to
metronidazole can be detected in up to 40% of stains, whereas
clarithromycin resistance is approximately 11%. Resistance to
tetracycline and amoxicillin is unusual, generally less than 1%.[62,63]
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In the United States, clarithromycin and metronidazole resistance
increase with age and are more common in women than in men.
Clarithromycin resistance is more common in the mid-Atlantic and
northeast regions of the country. Metronidazole resistance is more
common in Hispanics and Asians.
Antibiotic resistance significantly affects the success of PPI triple
regimens but is less important with bismuth-based regimens.[50] A
bacterial point mutation(s) that prevents reduction of metronidazole to its
active metabolite is responsible for drug resistance.[45] Resistance to
metronidazole appears to be a relative condition that can be overcome in
most instances by using a higher dose (500 mg) or combining the drug
with a bismuth preparation. On the other hand, clarithromycin resistance
appears to be an absolute situation that cannot be easily overcome by
increasing the macrolide dose.
One of three bacterial point mutations within its conserved loop of
23S strand of ribosomal RNA (A2143G, A2142G, and A2142C) can
interfere with ribosomal macrolide binding and lead to clarithromycin
resistance.[45] The A2143G mutation appears to have the greatest negative
effect on treatment and is likely the major reason for PPI triple therapy
failure. Testing for specific mutations is not clinically available, so if
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clarithromycin resistance is suspected or confirmed by culture, non-
macrolide regimens or sequential therapy are appropriate treatment
options.
Failed attempts at eradication generally result in secondary
antibiotic resistance.[49] Therefore,  one  can  assume when  treatment  with
clarithromycin or metronidazole-containing regimens is unsuccessful,
specific drug resistance has emerged which should influence any
subsequent choice of therapy.[45]
Treatment-related side effects can occur in as many as 50% of
patients taking one of the treatment regimens described previously, but
generally these are mild and do not require discontinuation of therapy.
Some of the more common side effects include taste alteration and
gastrointestinal (GI) upset with metronidazole and clarithromycin and
allergic reactions and diarrhoea with amoxicillin. In addition, tetracycline
should not be prescribed to children or pregnant women.
HELICOBACTER PYLORI AND TYPE 2 DIABETES MELLITUS
Infection with H.pylori is associated with increased levels of fetuin
A and associated insulin resistance, which may be evidence of a link with
diabetes, say researchers.
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"Among the various factors capable of inducing insulin resistance,
the up regulation of ?2-Heremans Schmid glycoprotein, also known as
human fetuin A, has been linked with impaired insulin sensitivity,
glucose metabolism and, subsequently, the onset of diabetes mellitus,"
explain Spyros Potamianos (University of Thessaly, Larissa, Greece)
Certain pathogens increase levels of fetuin A. To investigate
whether H.pylori is such an infection,  levels of fetuin A  were measured
and fasting insulin and glucose in 105 non-diabetic patients who were
undergoing esophagogastroduodenoscopy due to dyspeptic complaints.
As reported in the journal Diabetologia, 72 participants were found
to be infected with H. pylori and 33 were not. In multivariate analysis
(adjusted for age, gender, body mass index, lipids, and C-reactive
protein), H.pylori  positive individuals had significantly higher levels of
fetuin A (0.74 vs 0.57 g/l) and homeostasis model assessment of insulin
resistance (2.6-2.8 vs 1.9-2.0) than those who were not infected.
However, fasting glucose concentrations were similar between the
two groups. Potamianos and team conclude that the "data from the
present study are consistent with the notion that H. pylori infection may
induce insulin resistance."
36
The authors caution that "the present model cannot be regarded as
final, since it was shaped based upon the findings of a study of a more or
less observational nature."
They conclude: "Further research is therefore required, preferably
using a more 'mechanistic' approach so that the conclusions presented
above may be verified, and perhaps expanded by the inclusion of other
constituents, eg, adipokines, gastrin or somatostatin, before a widely
accepted mechanism is completely established."
STUDY SHOWING INCREASED PREVALENCE OF
HELICOBACTER PYLORI IN TYPE 2 DIABETES MELLITUS
1. Association between Type 2 diabetes mellitus and Helicobacter pylori
infection. Bener A, Micallef R et al
Turkish Journal of Gastroenterology. 2007 Dec;18(4):225-9.
The aim of this study was to determine the association between
Helicobacter pylori infection and Type 2 diabetes mellitus in the United
Arab Emirates population. This was case control study comparing 210
type 2 diabetics and 210 non- diabetic subjects. H.pylori was found by
histopathological examination by measuring antibody profiles among
type 2 diabetes mellitus patients and the non-diabetic group.
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The mean age of type 2 diabetes mellitus patients infected with
Helicobacter pylori was 48.1 +/- 7.9  years compared to 46.7 +/- 5.4 years
in the non-diabetic infected subjects. A positive antibody titer for
Helicobacter pylori infection (IgA >or=300) was found in 76.7% of the
diabetic subjects compared to 64.8% of the non-diabetic subjects
(p<0.009). There was higher prevalence of H.pylori infection in diabetic
obese patients than the non-diabetic subjects (23.6% vs 11.8%,
p<0.001).This study suggested that there is a significant association
between Helicobacter pylori infection and type 2 diabetes mellitus.
STUDY WHICH DID NOT SHOW ANY ASSOCIATION
BETWEEN TYPE 2 DIABETES AND H.PYLORI
1. Prevalence of Helicobacter pylori infection in patients with diabetes
mellitus
Ciortescu  I,  Sfarti  C.et  al  Rev  Med  Chir  Soc  Med  Nat  Iasi.  2009  Oct-
Dec;113(4):1048-55.
100 patients with diabetes mellitus type 1 and 2 (41 men and 59
women, mean age 58.59) were studied. Each patient did a self-report
questionnaire to get information regarding the presence and severity of
upper gastrointestinal tract symptoms. H. pylori status was confirmed by
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serological test and histopathology study of gastric biopsy or 13C-urea
breath test. Prevalence of H. pylori infection was found not to be
significantly higher in diabetics than in controls (70% vs 73%). 49% H.
pylori positive diabetics had type 2 diabetes mellitus, 27% had type
1 diabetes mellitus, with no statistically significant difference
(p > 0.05).The authors found no statistically significant difference in the
symptoms score between H. pylori positive and H.pylori negative
diabetic patients. The main value of HbA1c levels in H. pylori--infected
diabetics was 7.31% and 7.47% in H. pylori non-infected diabetics,
without significant difference. The authors concluded that there was no
statistically significant difference in the prevalence of H. pylori infection
between diabetics and non-diabetics patients and no difference in the
symptoms score between H. pylori positive and H. pylori negative
diabetic patients. H. pylori in diabetics appears to have no influence
glycemic status.
HelicotecUT®- rapid urease test.
HelicotecUT® is designed to detect the urease activity of
Helicobacter pylori in gastric mucosal biopsies. H. pylori produce large
amounts of the enzyme urease which exhibits the ability to hydrolyze
urea into ammonium ion and bicarbonate. When a tissue specimen from a
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patient is immersed in the HelicotecUT® test gel, the elevated pH level
produced by the presence and activity of urease is indicated by a colour
change of pH indicator in the test gel.
 If the gel changes colour from yellow to pink or red, then the test
of Helicobacter pylori is positive.
If the gel colour remains yellow after 24 hours, then the test is
negative
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AIM  AND OBJECTIVES OF THE STUDY
? To determine the frequency of Helicobacter pylori (H. pylori)
infection in type 2 diabetic and non-diabetic patients with
dyspepsia
? To study the relationship between glycemic control and
helicobacter pylori infection.
? To compare rapid urease test with histopathological examination of
helicobacter pylori infection
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MATERIALS AND METHODS
? This case-control study was carried out in our  Department of
Digestive Health and Diseases (DDHD),Government peripheral hospital
,Chennai from October  2011 to   February  2012.
? This is a hospital-based prospective case-control study
conducted on 100 subjects who had dyspepsia as defined as
pain or discomfort centered in the upper abdomen or bloating or
vomiting or combination of any two symptoms.
? They were divided into two groups i.e. type 2 diabetics and
non-diabetics; each group consisting of 50 patients.
? 100 patients between the age 25-60 yrs. with diabetes (50) and
non-diabetics (50) were enrolled in this study.
? All non diabetic patients were subjected to Random blood
glucose, blood urea, serum creatinine,liver function tests,
ultrasound abdomen prior to gastroscopy whereas diabetic
patients were subjected in addition to the above tests ,fasting
and post prandial blood glucose , glycosylated haemoglobin
tests.
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? Helicobacter pylori testing by rapid urease test (helicotec UT,
Strong biotech corp, Taiwan) and histological examination by
antral and   corpal biopsy done using gastroscopy.
? Ethical committee approval was obtained from Kilpauk
medical college before starting the study.
? Written informed consent was obtained from all participating
subjects in regional language (Tamil). Privacy was ensured.
? Statistical analysis was done by statistical analysis software
SPSS (version 15.0) for windows.
The inclusion criteria of the study were:
(1)   Dyspeptic patients above 25 years of age and below 60 years of
age,
(2)   Either gender,
(3)   Patients with history of dyspepsia, bloating or vomiting for more
than one month seen in our outpatient department (OPD),
 (4)  patients  who were known cases of Type 2 diabetes mellitus and
came with history of dyspepsia, vomiting, or bloating for more
than one month.
43
The exclusion criteria of the study were:
 (1)  Patients of type-1 diabetes
 (2)  Non-cooperative patients who refuse to give consent or participate
in the study
(3)  Patients below the age of 25 years and above the age of 60 years
(4)  Patients with gastric ulcer or erosions, duodenal ulcer or erosions,
gastro oesophageal reflux disease and gastric malignancy
(5)  Patients on  glucosidase inhibitors
(6)  Patients already treated for helicobacter pylori
(7)  Patients on proton pump inhibitors or H2 receptor antagonists in
the past  six weeks prior to the study
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RAPID UREASE TEST KIT USED IN THIS STUDY- HelicotecUT®
PLUS
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RESULTS AND STATISTICAL ANALYSIS
A total of 100 patients were recruited for this study (50 Type 2
diabetic  patients and 50 non diabetic patients who acted as controls).
Of the 50 non diabetic patients, 2 had gastric ulcer and 1 had
duodenal ulcer  and were excluded from this study according to the
exclusion criteria. Of the 50 diabetic patients, 2 patients had growth
stomach and hence were  excluded from this study according to the
exclusion criteria. 47 patients were studied in non diabetic group and 48
in  diabetic group ,totalling 95 patients. 55 patients were males (30 non
diabetic and 25 diabetics). 40 patients were females (17 non diabetic and
23 diabetic). 74 patients had abdominal pain (non diabetic 36 and
diabetic 38). 3 patients had abdominal bloating.
All were diabetics vomiting alone occurred in one non diabetic
patient. 2 non diabetic patients had both bloating and vomiting. 4 non
diabetic patients had abdominal pain and vomiting. 4 non diabetic
patients had abdominal pain and bloating and 7 diabetic patients had
abdominal pain and bloating. 26 patients were smokers (17 non diabetics
and 9 diabetics).
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21 patients consumed alcohol (15 non diabetics and 6 diabetics). 42
patients had fatty liver in ultrasound (10 non diabetics and 32  diabetics).
62 patients had Rapid urease test positive for helicobacter pylori
(22 non  diabetics and 40 diabetics). 50 patients had Histopathology
positive for helicobacter pylori (16  non diabetics and 34 diabetics).
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STATISTICAL ANALYSIS
Sex
Crosstab
Group
Non-
Diabetics Diabetics
Sex Male Count 30 25
% within Sex 54.5% 45.5%
% within Group 63.8% 52.1%
Female Count 17 23
% within Sex 42.5% 57.5%
% within Group 36.2% 47.9%
Total Count 47 48
P value – 0.246 (statistically not significant) using Pearson Chi-Square
tests.
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SYMPTOM  ANALYSIS
Crosstab
Group
Non-
Diabetics Diabetics
SYMPTOM
ANALYSIS
A Count 36 38
% within
HISTORY 48.6% 51.4%
% within
Group 76.6% 79.2%
AB Count 4 7
% within
HISTORY 36.4% 63.6%
% within
Group 8.5% 14.6%
AV Count 4 0
% within
HISTORY 100.0% .0%
% within
Group 8.5% .0%
B Count 0 3
% within
HISTORY .0% 100.0%
% within
Group .0% 6.3%
BV Count 2 0
% within
HISTORY 100.0% .0%
% within
Group 4.3% .0%
V Count 1 0
% within
HISTORY 100.0% .0%
% within
Group
2.1% .0%
Total Count 47 48
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ABD
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NG
A- ABDOMINAL PAIN
B- BLOATING
V-VOMITING
AV- ABDOMINAL PAIN AND VOMITING
AB- ABDOMINAL PAIN AND BLOATING
BV-BLOATING AND VOMITING
P value – 0.054 ( statistically not significant) using Pearson Chi-Square
tests.
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ND – NON DIABETICS
D – DIABETICS
SMOKING
Crosstab
Group
Non-Diabetics Diabetics
SMOKING Yes Count 17 9
% within
SMOKING 65.4% 34.6%
% within
Group 36.2% 18.8%
No Count 30 39
% within
SMOKING 43.5% 56.5%
% within
Group 63.8% 81.3%
Total Count 47 48
P value – 0.057 ( statistically not significant) using Pearson Chi-Square
tests.
ND – NON DIABETICS
D – DIABETICS
ALCOHOL
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Crosstab
Group
Non-
Diabetics Diabetics
ALCOHOL Yes Count 15 6
% within
ALCOHOL 71.4% 28.6%
% within
Group 31.9% 12.5%
No Count 32 42
% within
ALCOHOL 43.2% 56.8%
% within
Group 68.1% 87.5%
Total Count 47 48
P value – 0.023 ( statistically not significant) using Pearson Chi-Square
tests.
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Ultrasound abdomen
Crosstab
Group
Non-
Diabetics Diabetics
USG Normal Count 37 16
% within USG 69.8% 30.2%
% within Group 78.7% 33.3%
Fatty Count 10 32
% within USG 23.8% 76.2%
% within Group 21.3% 66.7%
Total Count 47 48
P value < 0.001 (statistically highly significant) using Pearson
Chi-Square tests.
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Crosstab
Group
Non-
Diabetics Diabetics
RUT Positive Count 22 40
% within
RUT 35.5% 64.5%
% within
Group 46.8% 83.3%
Negative Count 25 8
% within
RUT 75.8% 24.2%
% within
Group 53.2% 16.7%
Total Count 47 48
P value <  0.001 ( statistically highly significant) using Pearson Chi-
Square tests.
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Histopathology
Crosstab
Group
Non-
Diabeti
cs
Diabeti
cs
HISTOLOGY Positive Count 16 34
% within
HISTOLOGY 32.0% 68.0%
% within Group 34.0% 70.8%
Negative Count 31 14
% within
HISTOLOGY 68.9% 31.1%
% within Group 66.0% 29.2%
Total Count 47 48
P value < 0.001 ( statistically highly significant) using Pearson Chi-
Square tests.
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Crosstabs
HBA1C * RUT
Crosstab
RUT
Positive Negative
P value
HBA1C Count 6 0
% within
HBA1C 100.0% .0%
Upto 7
% within
RUT 15.0% .0%
Count 24 4
% within
HBA1C 85.7% 14.3%
7-9
% within
RUT 60.0% 50.0%
Count 10 4
% within
HBA1C 71.4% 28.6%
Above 9
% within
RUT 25.0% 50.0%
Total Count 40 8
0.254
P value  – 0.0254 ( statistically not significant) using Pearson Chi-Square
tests.
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FBS * RUT
Crosstab
RUT Total
Positive Negative
FBS Upto
100
Count 3 0 3
% within
FBS 100.0% .0% 100.0%
% within
RUT 7.5% .0% 6.3%
100-
140
Count 19 3 22
% within
FBS 86.4% 13.6% 100.0%
% within
RUT 47.5% 37.5% 45.8%
Above
140
Count 18 5 23
% within
FBS 78.3% 21.7% 100.0%
% within
RUT 45.0% 62.5% 47.9%
Total Count 40 8 48
P value – 0.557 (statistically not significant) using Pearson Chi-Square
tests.
60
PPBS * RUT
Crosstab
RUT
Positive Negative
PPBS Upto
140
Count 1 0
% within PPBS 100.0% .0%
% within RUT 2.5% .0%
140-180 Count 9 0
% within PPBS 100.0% .0%
% within RUT 22.5% .0%
Above
180
Count 30 8
% within PPBS 78.9% 21.1%
% within RUT 75.0% 100.0%
Total Count 40 8
P value – 0.283 ( statistically not significant) using Pearson Chi-Square
tests.
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DISCUSSION
Helicobacter pylori is a common infection in type 2 diabetics and
these patients have colonisation of helicobacter pylori in the gastric
antrum .This is probably because of certain chemotactic factors like
tumour necrosis factor (TNF), interleukins like IL1, IL2, IL8 which are
present in the gastric epithelium which do not confer protective immunity
against helicobacter pylori but cause a number of changes in the gastric
epithelium that promote inflammation and epithelial damage. The normal
(helper T cell) TH1 cells boost cell mediated immunity to cancer and
intracellular infection, TH2 cells seems more general and secretory
immune response in mucosa. In helicobacter pylori infection TH1 cells
predominate but TH2 cells are totally absent in Type 2 diabetic patients
hence the helicobacter pylori infection is persistent.
The studies done to see the relationship between helicobacter
pylori infection and Type 2 diabetes mellitus are few in number and have
yielded mixed results. Few studies have reported a high incidence of
between helicobacter pylori infection in Type 2 diabetics while others
have failed to show the increased incidence of helicobacter pylori
infection in dyspeptic patients with Type 2 diabetes mellitus.
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Our study has shown an increased incidence of helicobacter pylori
infection in Type 2 patients with dyspepsia as compared to non diabetic
controls. Our study showed 40/48(83.3%) patients were rapid urease test
positive for helicobacter pylori infection as compared to 22/47(46.8%) of
rapid urease test positive for helicobacter pylori infection in non diabetic
controls proving that infection with helicobacter pylori is increased in
Type 2 diabetics with dyspepsia which was statistically highly
significant( p value <0.001)
These results are comparable to a hospital based study done in
Pakistan with 148 patients who were divided into two groups of Type 2
diabetics and non diabetics each having a sample size of 74 patients.
They included all diabetic patients of age more than 35 years, both
genders with a history of, epigastric pain or bloating for more than one
month. Their analysis showed helicobacter pylori were positive in
54/74(73%) whereas in non diabetic patients’ helicobacter pylorus was
38/74(51.4%). This study in concurrence to our study concluded that
diabetic patients were more at risk of acquiring helicobacter pylori
infection. [64]
There was another study which was conducted in
Bikaner,rajasthan,India in 80 Type 2 diabetic patients . They studied the
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association of helicobacter pylori and non gastrointestinal complication of
Type 2 diabetes mellitus. They did gastroscopy and took gastric biopsy,
used rapid urease test to demonstrate helicobacter pylori infection. They
reported increased infection of helicobacter pylori in Type 2 diabetics.(p
value-<0.05 statistically significant).  [65]
However few other studies have shown a negative association of
helicobacter pylori in Type 2 diabetics. In a study conducted in china, 63
type 2 diabetics were studied of which 29 had upper gastrointestinal
symptoms. The control group was age adjusted non diabetic patients with
dyspepsia. they did gastroscopy with antral mucosal biopsy and did rapid
urease test(CLO TEST). Their results were that helicobacter pylori
infection in Type 2 diabetics was 50.8% and in non diabetics was
56.4%.the statistical analysis was not significant. They reported that there
was no association between helicobacter pylori infection, glycemic status,
duration of disease and upper gastrointestinal symptoms.
In our study type 2 diabetic patients’ glycemic status was
compared to helicobacter pylori infection by rapid urease test. According
to their HbA1c levels they were divided into 3 groups of less than 7(good
control), 7 to 9(poor control) and more than 9(bad control).using pearson
chi square test the association of glycemia in all three groups was not
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statistically significant (p-value 0.254).Similarly Type 2 diabetics were
grouped into 3 groups based on fasting and postprandial blood glucose
levels. In fasting blood glucose the 3 groups were less than
100mg/dl,100-140mg/dl and more than 140 mg/dl and in postprandial
blood glucose 3 groups were less than 140 mg/dl,140-180 mg/dl and
more than 180 mg/dl and all were compared with rapid urease test for
helicobacter pylori. But it did not show statistical significance. P-value
FBS group (0.557) and PPBG group (0.283). hence we agree with the
Chinese study that glycemic control does not correlate with helicobacter
pylori infection inspite of the observation that helicobacter pylori was
more common in type 2 diabetic patients. [66]
Another study done in Romania also showed that helicobacter
pylori in diabetics had no correlation with glycemic status. They
compared helicobacter pylori infection in both Type 1 and type 2
diabetics. They confirmed helicobacter pylori infection by serological test
and histopathological examination of gastric biopsy or 13 C urea breath
test. They showed 49% patients with Type 2 diabetics were positive for
helicobacter pylori.
In our study there was a discordance between helicobacter pylori
diagnosed by rapid urease test and by histopathology examination which
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was done by routine hematoxylin and eosin stain.(62/95 rapid urease test
positive as  compared to 50/95 by histopathology).This discordance might
be due to absence of routine use of special stains for staining helicobacter
pylori like modified giemsa, silver stains etc., which might aid in
diagnosing helicobacter pylori better. Hence we conclude that it is very
advantageous for the gastroenterologist to use rapid urease test at
endoscopy room to diagnose and treat helicobacter pylori early.
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CONCLUSION
1.  This study proves that the prevalence of helicobacter pylori is
markedly high in Type 2 diabetic patients than non diabetic
patients with dyspepsia.
2.  Glycemic levels in Type 2 diabetic patients had no statistically
significant correlation to helicobacter pylori positivity by rapid
urease test.
3.  Rapid urease test was more sensitive in diagnosing helicobacter
pylori compared to routine histopathological examination.
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 PROFORMA
Name of the patient:
Age:
Sex :
Occupation:
Phone number:
DDHD NO:
Address:
Clinical history:
Personal history
                                 Smoking :
                                 Alcohol:
Family history
                                Diabetes:
                                Hypertension:
Fasting blood glucose level:
Post prandial blood glucose level:
Hba1c:
Blood urea :
Serum creatinine :
Liver function tests:
Ultrasound abdomen:
S.No. DDHD NO NAME AGE SEX HISTORY SMOKINGALCOHOL
F/O
DIABETES
F/O
HT RBS UREA
CREAT-
ININE BILIRUBINAST ALT ALP USG RUT HISTOLOGY
1 6242/11 JANAKIRAMAN 44 M AB Y N N N 87 28 0.7 0.7 28 22 39 F P N
2 6916/11 PALANISAMY 42 M AV Y Y N N 98 22 0.8 0.9 44 33 55 N N N
3 6769/11 MANI 55 M A Y Y N N 117 29 0.7 0.3 38 32 43 N P P
4 6560/11 JEEVA 28 M A N N N N 110 24 1.1 0.7 43 19 45 N N N
5 6581/11 PARVATHI 37 F A N N N N 119 15 0.7 0.9 17 11 58 N N N
6 6111/11 GNANAVEL 39 M A N N N N 121 17 0.9 1.1 18 20 77 F P P
7 6384/11 VELANKANNI 34 F A N N N N 64 28 0.8 1 24 20 93 N N N
8 5691/11 SATHYAM 35 M A N Y N Y 78 33 0.9 0.8 23 22 55 N N N
9 6723/11 SARASWATHY 39 F A N N N N 88 21 0.7 0.8 19 19 58 N P P
10 7020/11 CHIDAMBARAM 48 M V Y N Y N 122 27 0.7 0.9 17 34 111 N P P
11 7110/11 SIVA 22 M A Y Y N N 98 22 1.2 0.5 34 34 98 N N N
12 3381/09 PARVATHY 45 F A N N N N 112 34 0.8 0.7 25 22 77 N P P
13 7654/11 RAVI 42 M A N Y N N 136 19 0.9 0.3 33 31 89 F N N
14 7537/11 MUNIRATHINAM 35 M A N N N N 87 17 0.8 1 23 18 94 N N N
15 7188/11 SARAVANAN 46 M A Y Y N N 97 33 0.7 1 25 44 88 N P P
16 7740/11 HUSSAIN 33 M A N N Y Y 112 24 0.8 0.9 27 16 98 N N N
17 7169/11 KUPPUSAMY 50 M A Y Y Y Y 111 25 0.9 0.7 19 16 77 N P P
18 6934/11 MALA 49 F A N N N N 96 33 1.1 0.5 16 14 121 F P P
19 6318/11 GNANAPRAKASH 23 M A Y Y N N 116 27 0.7 0.7 14 10 85 N P P
20 6863/11 CHANDRAN 50 M A Y Y Y N 145 21 0.7 0.83 18 37 127 N N N
21 6777/11 HAMEED 32 M AB N Y N N 105 25 0.6 0.31 42 36 47 F P N
22 6545/11 MEIYAMMAI 52 F BV N N N N 110 28 0.7 0.9 19 22 37 N N N
23 6342/11 MANIBASHYAM 45 M A Y N N N 122 34 0.6 0.5 17 17 98 F N N
24 7232/11 MANIVANNAN 55 M A Y Y N N 98 26 0.6 0.3 37 32 77 N N N
25 6989/11 SURYA 34 F AV N N N N 78 18 0.7 0.9 33 22 56 N P N
26 6453/11 VIJAYALAKSMI 54 F A N N N N 88 22 0.7 0.8 35 26 67 N N N
27 7685/11 MARIAMMAL 44 F A N N N N 113 26 1.1 0.7 22 27 99 N P P
28 7555/11 KAMALAM 56 F A N N N Y 137 33 1.2 0.6 29 26 67 N N N
29 6983/11 VIMAL 44 M A N N N N 143 34 0.9 0.5 30 18 111 N N N
30 6857/11 VINAY 26 M A N Y N N 112 18 0.8 1 38 19 78 N N N
31 7564/11 MUNUSAMY 34 M A Y N N N 143 17 0.7 1.1 24 20 76 F N N
32 7681/11 RATHINAM 33 F AV N N N N 97 22 0.7 0.9 27 30 65 N P N
33 7932/11 RAMATHAL 43 F AB N N N N 76 28 0.9 0.6 34 33 98 N P P
34 6565/11 KARTHY 27 M AB N N Y N 78 32 0.8 0.4 34 43 75 N N N
MASTER CHART
Non diabetic patients
S.No. DDHD NO NAME AGE SEX HISTORY SMOKINGALCOHOL
F/O
DIABETES
F/O
HT RBS UREA
CREAT-
ININE BILIRUBINAST ALT ALP USG RUT HISTOLOGY
35 7654/11 VIMALA 29 F A N N N N 113 19 0.9 0.9 19 22 74 N N N
36 7641/11 MUTHU 44 M A N N N N 142 33 0.7 0.7 18 21 87 F P P
37 6132/11 BALA 43 M A Y Y N Y 153 22 0.7 1 22 19 96 F P P
38 7132/11 RAMU 36 M A Y Y N N 123 19 0.9 0.8 20 22 75 N N N
39 7342/11 JEEVA 37 M A Y N N N 133 24 1.1 0.7 27 27 56 N P P
40 7251/11 FATHIMA 33 F BV N N N N 98 28 1.2 0.7 33 33 87 N N N
41 6712/11 JENCY 30 F A N N N N 78 32 0.9 0.6 38 32 88 N N N
42 7932/11 GANESH 54 M A N N Y N 132 23 0.7 0.9 26 22 99 N P N
43 7812/11 PAPPAMMAL 53 F A Y N N N 88 19 0.9 1 26 28 66 N N N
44 6767/11 KOODESWARAN 33 M A N N N N 76 17 0.8 0.4 19 27 68 N P P
45 7122/11 PALANIVE 23 M A N N N N 88 22 0.8 0.3 17 19 99 N P P
46 7341/11 KANAMMAL 44 F AV N N N N 132 24 0.7 0.7 27 20 44 N P N
47 6798/11 GOPU 55 M A Y Y N N 138 18 0.7 0.9 33 40 57 F N N
S.No. DDHD NO NAME  AGE SEX HISTORY SMOKING
ALC-
OHOL F/O DIABETESF/O HT FBS PPBS HBA1C UREA CREATININE BILIRUBIN AST ALT ALP USG RUT
HIST-
OLOGY
1 6776/11 RAVI 41 M B N N Y Y 95 136 8.8 33 1.1 0.6 55 22 66 N P P
2 6339/11 SRIDAR 43 M A N N Y N 136 212 7.56 31 0.8 0.4 40 32 57 N P N
3 275/11 SELVI 30 F A N N N N 111 245 8.5 34 0.8 0.8 33 26 84 F P P
4 6403/11 KANNAGI 38 F AB N N N N 216 315 10.1 36 1 0.7 28 22 44 F P P
5 6633/10 MURALIDHARAN56 M A N N Y N 180 286 8.85 23 0.7 1.1 16 11 63 F N P
6 7009/11 MANONMANI 45 F A N N Y Y 117 225 6.2 25 0.6 0.9 45 44 112 N P N
7 6578/11 RANI 50 F A N N Y Y 211 300 9.8 34 0.5 0.3 58 50 43 F P P
8 6634/11 JEBIN 38 F A N N Y N 146 215 9.4 33 0.3 0.4 54 33 44 F P P
9 6861/11 HARICHANDRAN58 M A N N N N 112 212 7.9 41 1.1 1.2 33 28 67 N P P
10 7341/11 SUBASH 58 M AB N N N N 113 188 6.9 27 1.2 1.1 24 16 88 F P N
11 7311/11 KANCHANA 55 F A N N Y N 233 345 12.5 44 0.6 0.7 18 17 67 F N N
12 6233/11 ANEES 33 F A N N Y N 221 289 11.5 34 0.6 0.7 22 23 55 F N N
13 6544/11 AKIL 37 M A Y Y Y N 132 198 7.9 24 0.6 0.7 44 26 63 F P P
14 7891/11 SATHYA 39 F AB N N N N 142 231 9 33 0.7 0.4 44 44 110 F P P
15 7733/11 VASANTHA 44 F A N N N Y 132 237 7.8 34 1 0.3 33 24 102 F P N
16 6565/11 SHEILA 42 F A N N Y N 212 265 8.8 18 0.6 1 26 34 69 F P P
17 7782/11 MADASAMY 33 M A Y N N Y 200 342 9.5 33 0.5 0.6 28 18 80 N P P
18 7890/11 RAMESH 29 M A Y Y N Y 112 165 6.8 34 0.9 0.4 19 33 71 F P P
19 6743/11 KASI 56 M A N Y Y N 122 180 7 33 1 0.9 16 33 65 F P P
20 6567/11 MURUGAN 33 M A N N Y N 237 288 8.88 25 1.1 0.8 22 36 77 F N N
21 7453/11 KUPPAN 57 M A N N Y N 133 289 9.6 33 0.9 1.1 44 28 102 F N N
22 7890/11 KALINGA 56 M A N N Y N 110 179 7.9 44 0.8 0.8 53 30 78 N P P
23 6211/11 NOOR BEGUM44 F AB N N N N 98 143 6.7 26 0.8 0.6 33 18 98 N P P
24 6542/11 KEERTHI 33 F AB N N N Y 223 298 9.67 18 0.6 0.7 55 18 99 F P N
25 6790/11 GOPAL 29 M A Y Y N N 122 177 7.4 19 0.7 0.4 34 54 45 F P P
26 6334/11 JEMI 34 F A N N Y N 112 187 7.2 44 0.5 0.5 37 33 56 N P P
27 6733/11 JOHN 55 M A N N Y Y 156 200 8.5 23 0.3 0.9 35 38 84 N P P
28 7851/11 SUMATHY 54 F A N N Y Y 232 283 9.7 27 0.5 1 35 36 88 N N N
29 7382/11 JOSEPH 44 M A N N N N 132 215 7.6 45 1.1 0.4 55 23 93 F P P
30 7680/11 SEKAR 48 M A N N Y N 100 167 6.9 35 1 0.9 22 30 47 N P P
31 6744/11 SEMBA 45 F AB N N Y N 123 168 7.71 33 0.7 0.6 18 45 44 N P N
MASTER CHART
Diabetic patients
S.No. DDHD NO NAME  AGE SEX HISTORY SMOKING
ALCOH-
OL F/O DIABETESF/O HT FBS PPBS HBA1C UREA CREATININE BILIRUBIN AST ALT ALP USG RUT
HIST-
OLOGY
32 6044/11 ROSYLN 55 F B N N Y N 144 188 7.89 27 0.7 0.8 45 24 78 F P P
33 6977/11 AZMAL 44 M B Y N N N 156 234 9.8 18 0.5 0.3 22 33 103 F P P
34 7844/11 AMBAL 44 F A N N N N 132 212 7.6 20 0.9 0.9 35 45 111 F P P
35 7600/11 KAPIL 47 M A Y N Y N 177 231 9 30 0.5 1.1 55 23 121 F P P
36 6722/11 AMBUJAM 56 F A N N N N 214 299 9.67 33 0.6 0.9 34 36 77 F P P
37 7656/11 MANI 33 M A N Y Y N 123 198 7.22 34 1.1 0.7 38 45 69 F N N
38 7731/11 MANGATHA 40 F A N N Y Y 123 226 8.4 22 0.5 0.6 46 44 95 N P P
39 7380/11 MAPILLAI 49 M A N N N N 146 288 8.77 37 0.7 0.9 47 24 67 F P P
40 7390/11 ROSE 34 F AB N N N N 265 313 11.2 33 0.5 0.9 35 33 77 F P N
41 6733/11 KANI FATHIMA27 F A N N N N 255 377 12.3 28 0.6 0.3 22 43 88 F P P
42 6098/11 PANICKER 56 M A Y N N Y 123 188 7.9 33 0.9 0.7 19 33 86 N P P
43 7999/11 MANI 44 M A Y N N N 112 178 7.45 27 0.5 0.5 30 40 65 F P P
44 7556/11 ARUN 40 M A Y Y Y N 102 167 7.44 35 0.7 0.9 40 20 77 F P P
45 7677/11 ANAND 36 M A N N Y N 116 201 7.5 25 0.5 0.5 44 15 89 F N N
46 6444/11 INDIRA 54 F A N N N N 213 311 8.98 33 0.4 1 37 56 100 F P P
47 7609/11 BABU 44 M A N N N Y 266 344 9.33 18 0.7 1.2 38 33 57 N P P
48 7655/11 PICHAI 34 F A N N Y N 143 213 8.44 40 0.5 0.9 19 45 78 N P P
